Propranolol for treating Kaposi sarcoma in children and adults
Treatments studied
Part of Cancer, Infections clinical trials.
This study tests whether the beta-blocker medicine propranolol can control Kaposi sarcoma (KS). It may help shrink KS lesions and slow disease when standard cancer medicines aren’t urgently needed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have biopsy-proven Kaposi sarcoma with measurable lesions
- Your KS is not so urgent that you need chemotherapy right away
- Your heart, liver, and kidney test results are within allowed ranges
- If you have HIV, you must be on HIV treatment (ART) for at least 12 weeks and show the right pattern of disease change
- You cannot have a history of asthma or diabetes, and you must avoid pregnancy and breastfeeding
- You must not have serious breathing or bleeding symptoms from causes other than KS, and you must not use certain other heart medicines
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if the blood pressure medication propranolol can treat Kaposi Sarcoma (a type of skin cancer) in adults. You may be able to join if you have at least 7 measurable skin lesions and are otherwise healthy enough to take an oral pill.
This trial tests paclitaxel plus pegylated liposomal doxorubicin (two IV chemotherapy medicines) for HIV-related Kaposi sarcoma (KS). It may help shrink KS lesions and improve quality of life in people with certain stages of KS and enough heart, blood, and liver function to safely receive treatment.
This Phase 1/2 study tests PDS01ADC, a targeted cancer drug, for advanced Kaposi sarcoma (KS). It also studies how well the drug works when added to the immunotherapy M7824, especially if KS has not responded to prior treatments.
This trial tests an experimental drug (CYT107) that boosts the immune system to help fight Kaposi sarcoma in people with HIV who have a low CD4 count despite good HIV treatment. It aims to see if the drug can improve KS tumors and quality of life.
This Phase 1/2 study tests the medicine abemaciclib to shrink Kaposi sarcoma (KS) lesions and control the disease. It includes both people with HIV and people without HIV, and may help when KS has not responded well to prior treatment or when certain KS stages are present.
This trial studies ixazomib (a targeted anti-cancer medicine) to treat cutaneous (skin) Kaposi sarcoma. It aims to shrink measurable skin lesions and improve symptoms, especially in people living with HIV.
Hear when a new Kaposi Sarcoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.